IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas
Prnewswire· 2026-03-02 13:30
[https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg]SOURCE IceCure Medical## 21% [more press release views with Request a Demo]## Also from this source### IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026[IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...]### IceCure Announces Thomas Hos ...
Twin Vee PowerCats Co. Reports 2025 Financial Results
Accessnewswire· 2026-03-02 13:30
FORT PIERCE, FL / ACCESS Newswire / March 2, 2026 / Twin Vee PowerCats Co. (Nasdaq:VEEE),("Twin Vee" or the "Company"), a manufacturer, distributor, and marketer of power sport boats, today reported financial results for the year ended December 31, 2025, and provided a business update. According to the Company, fiscal 2025 marked a transition year for Twin Vee, as management executed a comprehensive operational reset. ...
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
Globenewswire· 2026-03-02 13:30
MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations reviewing the science and outcomes of Barostim therapy at the Technology and Heart Failure Therapeutics 2026 (THT) meeting. THT, the annual conference organized by the Cardiovascular Research Foundation® (CRF®), will b ...
OZOP Energy Solutions, Inc. Announces Addition of Seasoned Beverage Industry Executive Ty Gilmore to Varon Commercial Leadership
Globenewswire· 2026-03-02 13:30
WARWICK, NY, March 02, 2026 (GLOBE NEWSWIRE) -- OZOP Energy Solutions, Inc. (OTC: OZSC, “Company”) today highlighted the addition of Ty Gilmore to the commercial leadership team of Varon. Mr. Gilmore will serve as Chief Revenue Officer of Varon. He is a seasoned beverage industry executive with more than two decades of experience across national accounts, distribution, and operational leadership at large-scale, multi-billion-dollar consumer packaged goods companies. Most recently, Mr. Gilmore served as Pres ...
Fortitude Gold To Advance East Camp Douglas Property Through $40 Million Joint Venture
Accessnewswire· 2026-03-02 13:30
COLORADO SPRINGS, CO / ACCESS Newswire / March 2, 2026 / Fortitude Gold Corp. (OTCQB:FTCO) (the "Company") announced that it has entered into a Joint Venture Agreement (the "JV Agreement") with Hawthorne Land & Minerals, LLC ("Hawthorne") to accelerate the exploration and development of its East Camp Douglas property located in Mineral County, Nevada. Pursuant to the JV Agreement, the parties will form an operating subsidiary, East Camp Douglas, LLC (the "JV"), which will be funded through a strategic $40 m ...
AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease
Prnewswire· 2026-03-02 13:30
In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for induction delivered by subcutaneous (SC) injection versus placebo1 These data support strong efficacy of risankizumab in Crohn's disease while providing potential for an induction choice for patients1 The safety profile of risankizumab SC induction was consistent with its known profile in Crohn's disease, wi ...
Dime Announces Elevation of Charlie Terrasi to Head of Investor CRE and Multifamily
Globenewswire· 2026-03-02 13:30
HAUPPAUGE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Dime announced today the elevation of Charlie Terrasi to Head of Investor Commercial Real Estate and Multifamily. Mr. Terrasi will manage and oversee growth in the Company’s Investor CRE portfolio, in addition to his current oversight of the multifamily portfolio. Stuart H. Lubow, CEO and President, stated, "As a result of Charlie's successful leadership and management of the Bank’s multifamily portfolio, he will take on the additional responsibility of le ...
Adastra Holdings Announces Agreement to Sell Assets and Resignation of Director
TMX Newsfile· 2026-03-02 13:30
Langley, British Columbia--(Newsfile Corp. - March 2, 2026) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) ("Adastra" or the "Company") announces that Adastra Labs Inc. ("Adastra Labs"), a wholly-owned subsidiary of the Company, has entered into an asset purchase agreement dated February 27, 2026 with an arm's length purchaser (the "Purchaser"), pursuant to which Adastra Labs has agreed to sell certain cryoethanol and hydrocarbon extraction and processing equipment as well as packaging and labelling machi ...
SEALSQ to Showcase at Embedded World 2026 Quantum-Resistant Chips and Advanced ASIC Innovations by IC'Alps
Globenewswire· 2026-03-02 13:30
Geneva, Switzerland, March 02, 2026 (GLOBE NEWSWIRE) -- Discover more & book a meeting via: https://www.sealsq.com/embedded-world-2026 SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or the “Company”), a leader in semiconductors, public key infrastructure (PKI), and post-quantum technology hardware and software, today announced its participation in Embedded World 2026, alongside its ASIC (Application Specific Integrated Circuit) design services subsidiary IC’Alps. Embedded Word 2026 event will take place from March ...
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis
Globenewswire· 2026-03-02 13:30
HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the issuance of a new U.S. patent entitled “Fibroblast Cell Therapy for Treatment of Osteoporosis.” The United States Patent and Trademark Office has issued U.S. ...